Metformin may influence cancer cells indirectly by decreasing insulin levels or directly by influencing cancer cells’ viability via activation of AMPK signaling pathway [5, 7], but many other molecular mechanisms of metformin's action in cancer have also been demonstrated such as regulation of p53/REDD1 [9], modulation of DICER and c-MYC [24], and stimulation of inflammatory pathways [25]. The gene discussed is DDIT4; the disease is cancer.